Status:
UNKNOWN
To Study the Safety and Efficacy of Simvastatin in Patients With Hepatopulmonary Syndrome in Cirrhosis.
Lead Sponsor:
Institute of Liver and Biliary Sciences, India
Conditions:
Liver Cirrhosis
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
Hepatopulmonary syndrome (HPS) is a frequent pulmonary complication of end-stage liver disease that is characterized by decreased arterial oxygenation caused by intrapulmonary vascular dilatation. Due...
Detailed Description
Methodology: * Study population:All the consecutive patients of cirrhosis admitted to Hepatology department of ILBS will be evaluated for inclusion. * Study design: Double Blind randomized control tr...
Eligibility Criteria
Inclusion
- Diagnosed case of Hepato-pulmonary syndrome AaPO2 \> 15 mm Hg on standing room air arterial blood gas (ABG). PaO2\<80 mmHg for clinical HPS between 18-70 years of years
- Child A/B cirrhosis, Child C with CTP score of =/\<10
- Patient with no liver transplant option
Exclusion
- Child-C cirrhosis CTP \>10
- Very Severe HPS
- Acute-on-chronic liver failure
- Thrombosis of splenoportal axis
- Hepatocellular carcinoma
- Renal dysfunction
- Patients intolerant to beta blockers (history of hypotension or bradycardia)
- Contraindication for beta-blockers (history of chronic obstructive pulmonary disease, atrioventricular block)
- Pregnant females
- Refusal to participate in the study
- Hepatic Hydrothorax
Key Trial Info
Start Date :
February 26 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2023
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT05187715
Start Date
February 26 2022
End Date
October 1 2023
Last Update
March 15 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute of Liver & Biliary Sciences
New Delhi, National Capital Territory of Delhi, India, 110070